Primary Biliary Cholangitis
Umecrine Cognition AB focuses on primary biliary cholangitis, with clinical research centered on the symptoms that affect daily functioning in people living with this autoimmune liver disease.
- Hepatology
- Autoimmune cholestatic disease
- Liver-related symptom burden
The sponsor’s clinical activity is directed toward patients with non-cirrhotic disease and those with Child-Pugh class A cirrhosis, reflecting an interest in liver disease populations with preserved hepatic function.
Fatigue and Cognitive Symptoms
Its research places strong emphasis on fatigue and cognitive dysfunction associated with PBC, addressing two of the most burdensome non-structural manifestations of the disease.
- Chronic fatigue
- Cognitive impairment
- Neurocognitive symptom management
These areas point to a therapeutic interest in the neurological and quality-of-life consequences of cholestatic liver disorders.
Sleep and Neurosteroid-Related CNS Effects
The sponsor’s work also aligns with central nervous system-focused symptom research, particularly conditions linked to cognitive performance, alertness, and daytime functioning in liver disease.
- Neurosteroid modulation
- Central nervous system symptoms
- Functional cognitive outcomes
This therapeutic domain connects liver disease care with symptom-focused neurological research.
Clinical Pharmacology and Symptom-Targeted Treatment
Umecrine Cognition AB’s funded trial activity includes interest in clinical pharmacology, safety, and tolerability in relation to treatment of fatigue and cognitive symptoms in PBC.
- Symptom-targeted therapy
- Safety and tolerability assessment
- Pharmacokinetics
Its research activity spans multiple collaborating sites across Europe and other active countries, supporting clinical development in a rare liver disease setting.
